Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Genfit advances GFT-505 to phase II in type 2 diabetes

Sep. 20, 2010

Merck & Co. identifies new glucagon receptor antagonists

Sep. 20, 2010

FDA advisory committee does not recommend approval of lorcaserin for obesity

Sep. 20, 2010

Wintherix elects WX-04554 as lead drug for bone healing

Sep. 20, 2010

TransPharma completes phase Ia ViaDerm-GLP1 agonist trial

Sep. 17, 2010

Abbott responds to FDA advisory committee vote regarding sibutramine

Sep. 17, 2010

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Sep. 17, 2010

FDA approves Savient Pharmaceuticals' pegloticase for gout

Sep. 16, 2010

Galderma claims new inhibitors of ACAT-1

Sep. 16, 2010

Mimetica presents new modulators of melanocortin receptors

Sep. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...